Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01180374 · ClinicalTrials.gov registry record · Early Phase 1
The Effects of Cannabidiol and ∆-9-THC in Humans
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 27
- Enrollment target
NCT01180374 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 27 participants.
The verdict
NCT01180374, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Cannabis is the most commonly used illicit substance in the US and herbal cannabis consists of a number of cannabinoids including Δ-9 THC and CBD. This study will characterize the interactive effects of the two major components of cannabis i.e. Δ-9-THC and CBD.
Interventions
- DRUG Placebo
- DRUG Cannabidiol
- DRUG Delta-9-THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-02-01 |
| Est. Completion | 2014-10-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01180374
The ClinicalTrials.gov registry entry for NCT01180374 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01180374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01180374 about?
NCT01180374 is a clinical study titled "The Effects of Cannabidiol and ∆-9-THC in Humans". Cannabis is the most commonly used illicit substance in the US and herbal cannabis consists of a number of cannabinoids including Δ-9 THC and CBD. This study will characterize the interactive effects of the two major components of cannabis i.e. Δ-9-THC and CBD.
What is the current status of trial NCT01180374?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 27 participants. The study started on 2010-02-01. Estimated completion is 2014-10-06.
What interventions are being tested in trial NCT01180374?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG), Delta-9-THC (DRUG).
Who is sponsoring clinical trial NCT01180374?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.